Sp1, acetylated histone-3 and p300 regulate TRAIL transcription: Mechanisms of PDGF-BB-mediated VSMC proliferation and migration

Journal of Cellular Biochemistry

Volumn 113, Issue 8, 2012, Pages 2597-2606

  Azahri, Nor Saadah M ^a,b   Di Bartolo, Belinda A ^a   Khachigian, Levon M ^a   Kavurma, Mary M ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA   (Malaysia)

Author keywords

Proliferation and migration; Trail; Transcription; VSMC

Indexed keywords

HISTONE H3; PLATELET DERIVED GROWTH FACTOR; PROTEIN P300; TRANSCRIPTION FACTOR SP1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ARTICLE; CELL MIGRATION; CELL PROLIFERATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; VASCULAR SMOOTH MUSCLE CELL;

ANIMALS; BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CHROMATIN IMMUNOPRECIPITATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HISTONES; IMMUNOPRECIPITATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; P300-CBP TRANSCRIPTION FACTORS; PROTO-ONCOGENE PROTEINS C-SIS; RATS; REAL-TIME POLYMERASE CHAIN REACTION; SP1 TRANSCRIPTION FACTOR; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84862564473     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24135     Document Type: Article

References (49)

1. Billon N, Carlisi D, Datto MB, van Grunsven LA, Watt A, Wang XF, Rudkin BB. 1999. Cooperation of Sp1 and p300 in the induction of the CDK inhibitor p21WAF1/CIP1 during NGF-mediated neuronal differentiation. Oncogene 18:2872-2882. (Pubitemid 29250877)
2. Cairns BR. 2001. Emerging roles for chromatin remodeling in cancer biology. Trends Cell Biol 11:S15-S21.
3. Chan J, Prado-Lourenco L, Khachigian LM, Bennett MR, Di Bartolo BA, Kavurma MM. 2010. TRAIL promotes VSMC proliferation and neointima formation in a FGF-2-, Sp1 phosphorylation-, and NFkappaB-dependent manner. Circ Res 106:1061-1071.
4. Chen YJ, Wang YN, Chang WC. 2007. ERK2-mediated C-terminal serine phosphorylation of p300 is vital to the regulation of epidermal growth factor-induced keratin 16 gene expression. J Biol Chem 282:27215-27228.
5. Choi EA, Lei H, Maron DJ, Wilson JM, Barsoum J, Fraker DL, El-Deiry WS, Spitz FR. 2003. Stat1-dependent induction of tumor necrosis factor-related Apoptosis-inducing ligand and the cell-surface death signaling pathway by interferon b in human cancer cells. Cancer Res 63:5299-5307. (Pubitemid 37139844)
6. Choi J-H, Nam K-H, Kim J, Baek MW, Park J-E, Park H-Y, Kwon HJ, Kwon O-S, Kim D-Y, Oh GT. 2005. Trichostatin A exacerbates atherosclerosis in low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 25:2404-2409. (Pubitemid 41552662)
7. Corallini F, Celeghini C, Rizzardi C, Pandolfi A, Di Silvestre S, Vaccarezza M, Zauli G. 2007. Insulin down-regulates TRAIL expression in vascular smooth muscle cells both in vivo and in vitro. J Cell Physiol 212:89-95. (Pubitemid 46867590)
8. Davie JR, He S, Li L, Sekhavat A, Espino P, Drobic B, Dunn KL, Sun J-M, Chen HY, Yu J, Pritchard S, Wang X. 2008. Nuclear organization and chromatin dynamics-Sp1, Sp3 and histone deacetylases. Adv Enzyme Regul 48:189-208.
9. Dzau VJ, Braun-Dullaeus RC, Sedding DG. 2002. Vascular proliferation and atherosclerosis: New perspectives and therapeutic strategies. Nat Med 8: 1249-1256. (Pubitemid 35373556)
10. Evanko SP, Raines EW, Ross R, Gold LI, Wight TN. 1998. Proteoglycan distribution in lesions of atherosclerosis depends on lesion severity, structural characteristics, and the proximity of platelet-derived growth factor and transforming growth factor-beta. Am J Pathol 152:533-546. (Pubitemid 28106400)
11. Fu M, Zhu X, Zhang J, Liang J, Lin Y, Zhao L, Ehrengruber MU, Chen YE. 2003. Egr-1 target genes in human endothelial cells identified by microarray analysis. Gene 315:33-41. (Pubitemid 37214895)
12. Ghaffari S, Jagani Z, Kitidis C, Lodish HF, Khosravi-Far R. 2003. Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor. Proc Natl Acad Sci USA 100:6523-6528. (Pubitemid 36666614)
13. Hung J-J, Wang Y-T, Chang W-C. 2006. Sp1 deacetylation induced by phorbol ester recruits p300 to activate 12(S)-lipoxygenase gene transcription. Mol Cell Biol 26:1770-1785.
14. Kalkhoven E. 2004. CBP and p300: HATs for different occasions. Biochem Pharmacol 68:1145-1155. (Pubitemid 39094280)
15. Kavurma MM, Bennett MR. 2008. Expression, regulation and function of trail in atherosclerosis. Biochem Pharmacol 75:1441-1450. (Pubitemid 351375180)
16. Kavurma MM, Khachigian LM. 2003a. ERK, JNK, and p38 MAP kinases differentially regulate proliferation and migration of phenotypically distinct smooth muscle cell subtypes. J Cell Biochem 89:289-300. (Pubitemid 36547263)
17. Kavurma MM, Khachigian LM. 2003b. Sp1 inhibits proliferation and induces apoptosis in vascular smooth muscle cells by repressing p21WAF1/Cip1 transcription and cyclin D1-Cdk4-p21WAF1/Cip1 complex formation. J Biol Chem 278:32537-32543. (Pubitemid 37055691)
18. Kavurma MM, Schoppet M, Bobryshev YV, Khachigian LM, Bennett MR. 2008a. TRAIL stimulates proliferation of vascular smooth muscle cells via activation of NF-kappa B and induction of insulin-like growth factor-1 receptor. J Biol Chem 283:7754-7762.
19. Kavurma MM, Tan NY, Bennett MR. 2008b. Death receptors and their ligands in atherosclerosis. Arterioscler Thromb Vasc Biol 28:1694-1702.
20. Kirshner JR, Karpova AY, Kops M, Howley PM. 2005. Identification of TRAIL as an interferon regulatory factor 3 transcriptional target. J Virol 79:9320-9324. (Pubitemid 40934844)
21. Kuribayashi K, Krigsfeld G, Wang W, Xu J, Mayes PA, Dicker DT, Wu GS, El-Deiry WS. 2008. TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death. Cancer Biol Ther 7:2034-2038.
22. Lal G, Zhang N, van der Touw W, Ding Y, Ju W, Bottinger EP, Reid SP, Levy DE, Bromberg JS. 2009. Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J Immunol 182:259-273.
23. Leppanen O, Janjic N, Carlsson MA, Pietras K, Levin M, Vargeese C, Green LS, Bergqvist D, Ostman A, Heldin CH. 2000. Intimal hyperplasia recurs after removal of PDGF-AB and -BB inhibition in the rat carotid artery injury model. Arterioscler Thromb Vasc Biol 20:E89-E95.
24. Lusis AJ. 2000. Atherosclerosis. Nature 407:233-241.
25. Lynn Ray J, Leach R, Herbert J-M, Benson M. 2001. Isolation of vascular smooth muscle cells from a single murine aorta. Methods Cell Sci 23: 185-188. (Pubitemid 34863290)
26. Nelson JD, Denisenko O, Bomsztyk K. 2006. Protocol for the fast chromatin immunoprecipitation (ChIP) method. Nat Protoc 1:179-185.
27. Noiseux N, Boucher CH, Cartier R, Sirois MG. 2000. Bolus endovascular PDGFR-beta antisense treatment suppressed intimal hyperplasia in a rat carotid injury model. Circulation 102:1330-1336.
28. Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y. 1996. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87:953-959. (Pubitemid 26404293)
29. Papageorgiou A, Dinney CP, McConkey DJ. 2007. Interferon-alpha induces TRAIL expression and cell death via an IRF-1-dependent mechanism in human bladder cancer cells. Cancer Biol Ther 6:872-879. (Pubitemid 351574976)
30. Petersohn D, Thiel G. 1996. Role of zinc-finger proteins Sp1 and Zif268/egr-1 in transcriptional regulation of the human synaptobrevin II gene. Eur J Biochem 239:827-834. (Pubitemid 26253060)
31. Pons D, de Vries FR, van den Elsen PJ, Heijmans BT, Quax PHA, Jukema JW. 2009. Epigenetic histone acetylation modifiers in vascular remodelling: New targets for therapy in cardiovascular disease. Eur Heart J 30:266-277.
32. Raines EW. 2004. PDGF and cardiovascular disease. Cytokine Growth Factor Rev 15:237-254. (Pubitemid 38781049)
33. Rivera-Walsh I, Waterfield M, Xiao G, Fong A, Sun SC. 2001. NF-kappaB signaling pathway governs TRAIL gene expression and human T-cell leukemia virus-I Tax-induced T-cell death. J Biol Chem 276:40385-40388.
34. Romieu-Mourez Rl, Solis M, Nardin A, Goubau D, Baron-Bodo Vr, Lin R, Massie B, Salcedo M, Hiscott J. 2006. Distinct roles for IFN regulatory factor (IRF)-3 and IRF-7 in the activation of antitumor properties of human macrophages. Cancer Res 66:10576-10585.
35. Ross R. 1993. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 362:801-809. (Pubitemid 23132154)
36. Ross R. 1995. Cell biology of atherosclerosis. Annu Rev Physiol 57:791-804.
37. Ross R, Glomset JA. 1973. Atherosclerosis and the arterial smooth muscle cell: Proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 180:1332-1339.
38. Rubin K, Tingstrom A, Hansson GK, Larsson E, Ronnstrand L, Klareskog L, Claesson-Welsh L, Heldin CH, Fellstrom B, Terracio L. 1988. Induction of B-type receptors for platelet-derived growth factor in vascular inflammation: Possible implications for development of vascular proliferative lesions. Lancet 1:1353-1356.
39. Sano H, Sudo T, Yokode M, Murayama T, Kataoka H, Takakura N, Nishikawa S, Nishikawa SI, Kita T. 2001. Functional blockade of platelet-derived growth factor receptor-beta but not of receptor-alpha prevents vascular smooth muscle cell accumulation in fibrous cap lesions in apolipoprotein E-deficient mice. Circulation 103:2955-2960. (Pubitemid 32578134)
40. Seifert RA, Hart CE, Phillips PE, Forstrom JW, Ross R, Murray MJ, Bowen-Pope DF. 1989. Two different subunits associate to create isoform-specific platelet-derived growth factor receptors. J Biol Chem 264:8771-8778. (Pubitemid 19151598)
41. Selvi RB, Kundu TK. 2009. Reversible acetylation of chromatin: Implication in regulation of gene expression, disease and therapeutics. Biotechnol J 4: 375-390.
42. Tallquist M, Kazlauskas A. 2004. PDGF signaling in cells and mice. Cytokine Growth Factor Rev 15:205-213. (Pubitemid 38781046)
43. Thomas JA, Deaton RA, Hastings NE, Shang Y, Moehle CW, Eriksson U, Topouzis S, Wamhoff BR, Blackman BR, Owens GK. 2009. PDGF-DD, a novel mediator of smooth muscle cell phenotypic modulation, is upregulated in endothelial cells exposed to atherosclerosis-prone flow patterns. Am J Physiol Heart Circ Physiol 296:H442-H452.
44. Wamhoff BR, Hoofnagle MH, Burns A, Sinha S, McDonald OG, Owens GK. 2004. A G/C element mediates repression of the SM22a promoter within phenotypically modulated smooth muscle cells in experimental atherosclerosis. Circ Res 95:981-988. (Pubitemid 39532328)
45. Wang QD, Ji YS, Wang XF, Evers BM. 2000. Isolation and molecular characterization of the 50-upstream region of the human TRAIL gene. Biochem Biophys Res Commun 276:466-471.
46. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang C-P, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, Goodwin RG. 1995. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673-682. (Pubitemid 26091143)
47. Xiao H, Hasegawa T, Isobe K. 2000. p300 collaborates with Sp1 and Sp3 in p21(waf1/cip1) promoter activation induced by histone deacetylase inhibitor. J Biol Chem 275:1371-1376. (Pubitemid 30051195)
48. Yoshida T, Gan Q, Shang Y, Owens GK. 2007. Platelet-derived growth factor- BB represses smooth muscle cell marker genes via changes in binding of MKL factors and histone deacetylases to their promoters.Am J Physiol Cell Physiol 292:C886-C895.
49. Zhang C, Kavurma MM, Lai A, Khachigian LM. 2003. Ets-1 protects vascular smooth muscle cells from undergoing apoptosis by activating p21WAF1/ Cip1: ETS-1 regulates basal and inducible p21WAF1/Cip1 transcription via distinct CIS-acting elements in the p21WAF1/Cip1 promoter. J Biol Chem 278:27903-27909. (Pubitemid 36899983)